Innoviva (formerly Theravance) figures there's no sense in re-inventing the wheel. The biotech takes aim at already proven biological targets, taking advantage of existing research to create next-generation treatments. The firm is focused on the discovery, development, and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system pain. Its VIBATIV product (an injectable antibiotic approved to treat skin infections and hospital-acquired pneumonia) was successfully developed and commercialized with partner Astellas. It also develops chronic obstructive pulmonary disease (COPD) products with GlaxoSmithKline (GSK).